The biologics drugs discovery market is a risk-oriented place that require substantial amount of capital investment. Therefore, this makes the survival of any company in the market a challenging task. Not every company in the market has requisite capital and expertize for the research and development of the biological drugs, hence, they prefer to collaborate with other pharmaceutical companies or the Contract Research Organizations (CROs) which have a promising pipeline of biological candidates. Bigger companies are using mergers and acquisitions to acquire smaller players and stay ahead in the market.
The biologics drugs discovery market witnessed a collaboration between Zebra Biologics Inc. and AbbVie at the beginning of the year 2017. According to an announcement in the press release, Zebra aims to discover agonist antibody therapeutics for inflammatory diseases. Zebra will use its novel and patented function-based antibody discovery platform to generate antibodies that activate biological pathways associated with targets designated by AbbVie.
In February 2017, Albany Molecular Research Inc. (AMRI) announced in a press release that it has entered into an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high throughput mass spectrometry (MS) for drug discovery. Furthermore, in July 2017, Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) announced in a press release that the companies will discuss data supporting the ABP 215 Biologics License Application (BLA) with the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA). This product is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.1
The recent activities and market attractiveness have led to BIS Research compiling a report titled ‘Global Biologics Drug Discovery Market Analysis and Forecast, (2017-2025)'. According to the analyst, "The global biologics drug discovery market was estimated at $8.9 billion in 2016 and is estimated to grow over $22.7 billion by 2025. The introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future."
This report provides a holistic view of the biologics drug discovery market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The study considers the growth-share matrix model for a comprehensive study of the global biologics drug discovery market and assesses the factors governing the same.